Avacta Group (LON:AVCT) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Avacta Group Plc (LON:AVCT) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 67.90 and traded as high as GBX 72. Avacta Group shares last traded at GBX 70, with a volume of 1,221,742 shares changing hands.

Avacta Group Stock Up 2.2%

The company has a debt-to-equity ratio of 602.46, a current ratio of 0.89 and a quick ratio of 4.96. The firm’s 50-day moving average price is GBX 74.81 and its 200 day moving average price is GBX 67.90. The firm has a market capitalization of £327.98 million, a price-to-earnings ratio of -7.25 and a beta of 1.12.

Avacta Group (LON:AVCT) last issued its quarterly earnings data on Tuesday, May 19th. The biotechnology company reported GBX (9.27) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 2,929.47% and a negative net margin of 33,961.06%.The company had revenue of GBX 11 million for the quarter. Sell-side analysts expect that Avacta Group Plc will post -9.9011833 EPS for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).